Matches in Wikidata for { <http://www.wikidata.org/entity/Q45896479> ?p ?o ?g. }
- Q45896479 description "2015 nî lūn-bûn" @default.
- Q45896479 description "2015 թվականի նոյեմբերի 4-ին հրատարակված գիտական հոդված" @default.
- Q45896479 description "2015年の論文" @default.
- Q45896479 description "2015年学术文章" @default.
- Q45896479 description "2015年学术文章" @default.
- Q45896479 description "2015年学术文章" @default.
- Q45896479 description "2015年学术文章" @default.
- Q45896479 description "2015年学术文章" @default.
- Q45896479 description "2015年学术文章" @default.
- Q45896479 description "2015年學術文章" @default.
- Q45896479 description "2015年學術文章" @default.
- Q45896479 description "2015年學術文章" @default.
- Q45896479 description "2015年學術文章" @default.
- Q45896479 description "2015年學術文章" @default.
- Q45896479 description "2015년 논문" @default.
- Q45896479 description "article científic" @default.
- Q45896479 description "article scientific" @default.
- Q45896479 description "article scientifique" @default.
- Q45896479 description "articol științific" @default.
- Q45896479 description "articolo scientifico" @default.
- Q45896479 description "artigo científico" @default.
- Q45896479 description "artigo científico" @default.
- Q45896479 description "artigo científico" @default.
- Q45896479 description "artikel ilmiah" @default.
- Q45896479 description "artikull shkencor" @default.
- Q45896479 description "artikulong pang-agham" @default.
- Q45896479 description "artykuł naukowy" @default.
- Q45896479 description "artículo científico publicado en 2015" @default.
- Q45896479 description "artículu científicu" @default.
- Q45896479 description "bilimsel makale" @default.
- Q45896479 description "bài báo khoa học" @default.
- Q45896479 description "naučni članak" @default.
- Q45896479 description "scienca artikolo" @default.
- Q45896479 description "scientific article published on 4 November 2015" @default.
- Q45896479 description "scientific article published on 4 November 2015" @default.
- Q45896479 description "scientific article published on 4 November 2015" @default.
- Q45896479 description "teaduslik artikkel" @default.
- Q45896479 description "tieteellinen artikkeli" @default.
- Q45896479 description "tudományos cikk" @default.
- Q45896479 description "vedecký článok" @default.
- Q45896479 description "vetenskaplig artikel" @default.
- Q45896479 description "videnskabelig artikel" @default.
- Q45896479 description "vitenskapelig artikkel" @default.
- Q45896479 description "vitskapeleg artikkel" @default.
- Q45896479 description "vědecký článek" @default.
- Q45896479 description "wetenschappelijk artikel" @default.
- Q45896479 description "wissenschaftlicher Artikel" @default.
- Q45896479 description "επιστημονικό άρθρο" @default.
- Q45896479 description "мақолаи илмӣ" @default.
- Q45896479 description "наукова стаття, опублікована в листопаді 2015" @default.
- Q45896479 description "научна статия" @default.
- Q45896479 description "научная статья" @default.
- Q45896479 description "научни чланак" @default.
- Q45896479 description "научни чланак" @default.
- Q45896479 description "מאמר מדעי" @default.
- Q45896479 description "مقالة علمية نشرت في 4 نوفمبر 2015" @default.
- Q45896479 description "৪ নভেম্বর ২০১৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q45896479 description "บทความทางวิทยาศาสตร์" @default.
- Q45896479 description "სამეცნიერო სტატია" @default.
- Q45896479 name "Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC." @default.
- Q45896479 name "Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC." @default.
- Q45896479 type Item @default.
- Q45896479 label "Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC." @default.
- Q45896479 label "Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC." @default.
- Q45896479 prefLabel "Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC." @default.
- Q45896479 prefLabel "Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC." @default.
- Q45896479 P1433 Q45896479-E4153DA3-BD2C-4DDE-8521-1693F9BBB8E1 @default.
- Q45896479 P1476 Q45896479-8EC5FE73-87C5-479C-BA1D-BC12C931E9FC @default.
- Q45896479 P2093 Q45896479-707CFAC7-39B6-4E8D-9502-6D618E291296 @default.
- Q45896479 P2093 Q45896479-A29E0CC0-D302-4DBC-94D3-68D35C3C5B43 @default.
- Q45896479 P2093 Q45896479-AD7B4CFC-CDC5-48EA-AE5B-485DAE9E233E @default.
- Q45896479 P2093 Q45896479-E1E777DC-F633-4F2B-AA20-D61CCE41E7C8 @default.
- Q45896479 P2093 Q45896479-E63A6FAF-B236-489F-AB29-437CB900E2FB @default.
- Q45896479 P2093 Q45896479-EEC56962-1239-402A-889E-3DD06578F94A @default.
- Q45896479 P2093 Q45896479-F02A2FAF-8CBA-4996-A53B-BDEB751E92BF @default.
- Q45896479 P2093 Q45896479-F773318B-EEF8-4556-BB74-A587E162EC42 @default.
- Q45896479 P2093 Q45896479-FE10F60E-3771-446C-B567-6E28F23F8CBC @default.
- Q45896479 P2093 Q45896479-FE72C71C-ECD9-4ED0-A57F-7F591986D4C8 @default.
- Q45896479 P2888 Q45896479-B09B1DDB-98BA-429E-AB69-344296F31AC8 @default.
- Q45896479 P304 Q45896479-C284B355-FAAF-4B53-89AE-5A3BEC5F635C @default.
- Q45896479 P31 Q45896479-A4D9C36B-A006-451E-A4FC-1791A94E1548 @default.
- Q45896479 P356 Q45896479-5B40538D-890F-4F73-9290-393CB0E92CCB @default.
- Q45896479 P433 Q45896479-26A06718-D085-4F39-A719-7712BD79E8CC @default.
- Q45896479 P478 Q45896479-D0294548-C6BF-42D5-BCEB-8B7275F2775E @default.
- Q45896479 P50 Q45896479-441B68F7-0E27-413E-9A88-5C970E250280 @default.
- Q45896479 P50 Q45896479-C0605A98-793E-4602-AC4D-835571E42417 @default.
- Q45896479 P577 Q45896479-6896B7F9-51EA-47E9-BE0D-E4E6B2383EC6 @default.
- Q45896479 P5875 Q45896479-3DE33C47-A45C-444F-BD7B-D89E633706B0 @default.
- Q45896479 P6179 Q45896479-C01B15B2-9E5A-401A-BBD0-55903E512EA6 @default.
- Q45896479 P932 Q45896479-67A8EAD3-DD49-4536-A960-5B21D4C79B46 @default.
- Q45896479 P356 2051-1426-3-S2-P171 @default.
- Q45896479 P1433 Q27725163 @default.
- Q45896479 P1476 "Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC." @default.
- Q45896479 P2093 "Anthony Jarkowski" @default.
- Q45896479 P2093 "Fabrice Barlesi" @default.
- Q45896479 P2093 "Johan Vansteenkiste" @default.
- Q45896479 P2093 "Julie Brahmer" @default.
- Q45896479 P2093 "Luping Zhao" @default.
- Q45896479 P2093 "Naiyer Rizvi" @default.
- Q45896479 P2093 "Patrick Forde" @default.